15

CLAIMS

What is claimed is:

5	1.	A	method of screening for a compound which modulates
	phospholipase D	(PLD)	activity, comprising the steps of:

- a) combining a compound with phospholipase D (PLD), thereby forming a mixture;
- b) treating said mixture with phosphatidylcholine, such that a cleavage reaction between phosphatidylcholine and PLD can occur, resulting in generation of phosphatidic acid and choline; and
 - c) evaluating the amount of choline produced, such that a compound which modulates PLD activity is determined.
 - 2. The method of claim 1, wherein said compound inhibits PLD from cleaving phosphatidylcholine.
- 3. The method of claim 1, wherein said compound increases 20 cleavage of phosphatidylcholine by PLD.
 - 4. The method of claim 1, wherein step c) includes an oxidation step of choline.
- 25 5. The method of claim 4, wherein said oxidation step includes peroxidase, 4-aminoantipyrine, phenol and choline oxidase.
 - 6. The method of claim 1, wherein said compound is PSDP.
- The method of claim 1, wherein said compound is a PSDP analog.
 - 8. A method of screening for a compound which modulates intracellular signaling, comprising the steps of:
- a) combining a compound with phospholipase D (PLD), thereby forming a mixture;

15

20

25

30

- b) treating said mixture with phosphatidylcholine, such that a cleavage reaction between phosphatidylcholine and PLD occurs, resulting in generation of phosphatidic acid and choline; and
- c) evaluating the amount of choline produced, such that a compound which modulates intracellular signaling is determined.
 - 9. The method of claim 8, wherein said compound inhibits PLD from cleaving phosphatidylcholine.
- 10 10. The method of claim 8, wherein said compound increases cleavage of phosphatidylcholine by PLD.
 - 11. The method of claim 8, wherein step c) includes an oxidation step of choline.
 - 12. The method of claim 11, wherein said oxidation step includes peroxidase, 4-aminoantipyrine, phenol and choline oxidase.
 - 13. The method of claim 8, wherein said compound is PSDP.
 - 14. The method of claim 8, wherein said compound is a PSDP analog.
 - 15. A method of screening for a compound which associates with protein phosphate-sensing domains, comprising the steps of:
 - a) contacting a Gst-Grb2 fusion protein complexed to a support with a labeled lipid compound with; and
 - b) evaluating the amount of labeled compound associated with said protein.
 - 16. The method of claim 15. for ther comprising the step of treating said labeled lipid compound associated with a competing compound and evaluating the amount of labeled compound removed from said Gst-Grb2 fusion protein.
- The method of claim 15, wherein said support is agarose.

٠. à.

- 18. The method of claim 15, wherein said labeled lipid compound is radiolabeled.
- 19. The method of claim 18, wherein said radiolabeled compound is radiolabeled PSDP or a radiolabeled PSDP analog.
 - 20. The method of claim 16, wherein said competing compound is unlabeled PSDP, a PSDP analog, or delipidated albumin.
- 10 21. A method of screening for a compound which modulates the production of inositol trisphosphate, comprising the steps of:
 - a) treating polymorphonuclear leukocytes with a stimulation agent, causing activation of cell, thereby producing inositol trisphosphate;
 - b) treating said activated cells with a modulating compound;

15 and

30

- c) measuring the effect of said modulating compound on production of said inositol trisphosphate.
- 22. The method of claim 21, wherein said stimulation agent is fMLP, a leukotriene, a cytokine, gm-csf, a lipopolysaccharid or CFA.
 - 23. The method of claim 21, wherein said modulating compound is PSDP.
- 25 24. The method of claim 21, wherein said modulating compound is a PSDP analog.
 - 25. The method of claim 21, further including the step of contacting a radiolabel to said inositol trisphosphate of step c).
 - 26. The method of claim 21, wherein production of phospholipase C activity is determined.
- 27. A method of screening for a compound which modulates neutrophil activation, comprising the steps of:

10

- a) treating neutrophils with a stimulation agent, causing activation of said neutrophils, thereby producing inositol phosphate;
- b) treating said activated neutrophils with a modulating compound; and
- 5 c) measuring the effect of said modulating compound on production of said inositol phosphate.
 - 28. The method of claim 27, wherein said stimulation agent is fMLP, a leukotriene, a cytokine, gm-csf, a lipopolysaccharid or CFA.
 - 29. The method of claim 27, wherein said modulating compound is PSDP.
- 30. The method of claim 27, wherein said modulating compound is a PSDP analog.
 - 31. The method of claim 27, further including the step of contacting a radiolabel to said inositol phosphate of step c).
- 20 32. The method of claim 27, wherein production of phospholipase C activity is determined.